Full Text View
Tabular View
No Study Results Posted
Related Studies
HIV Infection and Tobacco Use Among Injection Drug Users in Baltimore, Maryland: A Pilot Study of Biomarkers
This study is currently recruiting participants.
Verified by National Institutes of Health Clinical Center (CC), March 2009
First Received: June 23, 2007   Last Updated: March 25, 2009   History of Changes
Sponsored by: National Cancer Institute (NCI)
Information provided by: National Institutes of Health Clinical Center (CC)
ClinicalTrials.gov Identifier: NCT00491335
  Purpose

Background:

The incidence of lung cancer is quite high among people with the human immunodeficiency (HIV) virus. Frequent smoking may explain that cancer increase, given that 50% to 70% of HIV-infected people are current smokers.

Recent research suggests that other factors may be involved as well. Smoking habits, such as smoking earlier in life or smoking more cigarettes a day than others do, may have a role. Also, HIV-infected smokers seem to have a greater risk of chronic obstructive pulmonary disease (COPD). The association of HIV and COPD is important, because COPD itself is linked to an increased risk of lung cancer.

About 1,600 subjects from the study known as ALIVE (AIDS Linked to the Intra-Venous Experience), which began in 1988 in Baltimore, Maryland, will be given a detailed questionnaire on smoking behaviors and lung cancer risk factors. They will also have spirometry testing, to evaluate lung function.

Objectives:

To better characterize smoking habits and compare tobacco use among HIV-infected and uninfected drug users.

To compare serum cotinine levels and spirometry results, as a marker of tobacco use and a marker of damage to lung function, respectively.

Eligibility:

Patients 18 years of age and older who are in the ALIVE cohort.

Design:

Patients undergo the following procedures:

  • Completing a questionnaire on smoking history. Questions include age when smoking began, periods of quitting smoking, average number of cigarettes per day for specific periods, amount of each cigarette smoked, depth of inhalation, type of cigarette, nicotine dependence, use of other smoked [Note: I would not mention that these drugs are illegal] drugs, exposure to environmental tobacco smoke, past medical history, and recent respiratory symptoms.
  • Spirometry testing. Patients are asked to breathe as deeply as possible and then rapidly exhale into a tube. The forced expiration volume in 1 second reflects the average flow rate during the first second, and it can be used to determine the degree of pulmonary obstruction.
  • Blood samples. Tests measure levels of cotinine, a chemical made by the body from nicotine. African American males, who constitute the majority of the ALIVE cohort, participate in this test. Results would show how much tobacco smoke has recently entered the body. For this test, researchers plan to evaluate 240 current tobacco smokers and 100 participants who report no recent cigarette use.

Condition
HIV Infections
AIDS
Lung Cancer
Tobacco Addiction
Drug Addiction

MedlinePlus related topics: AIDS Cancer Lung Cancer Smoking Smoking and Youth
U.S. FDA Resources
Study Type: Observational
Study Design: Prospective
Official Title: HIV Infection and Tobacco Use Among Injection Drug Users in Baltimore, MD: A Pilot Study of Biomarkers

Further study details as provided by National Institutes of Health Clinical Center (CC):

Estimated Enrollment: 1600
Study Start Date: June 2007
Detailed Description:

Lung cancer incidence is substantially elevated among people infected with human immunodeficiency virus (HIV). Although frequent smoking may partly explain this increase, recent work suggests other factors may also be involved. To better characterize smoking habits and lung cancer risk in HIV-infected people, the investigators propose a cross-sectional pilot study of HIV-infected and uninfected injection drug users in the ALIVE cohort in Baltimore, Maryland. A detailed questionnaire on smoking behaviors and other lung cancer risk factors will be administered to all ~ 1600 cohort subjects. In addition, the investigators will measure serum cotinine (a marker of recent smoking intensity) for a sample of 340 African American males from the cohort, stratified on the amount of cigarette use, HIV status, and CD4 count. Spirometry will be performed on the entire group of 1600 subjects, to assess for chronic obstructive pulmonary disease. Differences between HIV-infected and uninfected subjects in smoking habits, exposure to tobacco, or lung damage will identify areas for future investigation.

  Eligibility

Ages Eligible for Study:   17 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria
  • INCLUSION CRITERIA:

Must be a participant in the ALIVE Study

EXCLUSION CRITERIA:

Not a participant in the ALIVE Study

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00491335

Contacts
Contact: Eric A. Engels, M.D. (301) 435-4722 engelse@exchange.nih.gov

Locations
United States, Maryland
Johns Hopkins University Recruiting
Baltimore, Maryland, United States, 21205
Sponsors and Collaborators
  More Information

Publications:
Study ID Numbers: 999907173, 07-C-N173
Study First Received: June 23, 2007
Last Updated: March 25, 2009
ClinicalTrials.gov Identifier: NCT00491335     History of Changes
Health Authority: United States: Federal Government

Keywords provided by National Institutes of Health Clinical Center (CC):
AIDS
Lung Cancer
Emphysema
Nicotine
HIV Infection
Lung Cancer
Smoking

Study placed in the following topic categories:
Nicotine polacrilex
Thoracic Neoplasms
Emphysema
Behavior, Addictive
Sexually Transmitted Diseases, Viral
Acquired Immunodeficiency Syndrome
Disorders of Environmental Origin
Impulsive Behavior
Immunologic Deficiency Syndromes
Pulmonary Emphysema
Virus Diseases
Compulsive Behavior
Smoking
Respiratory Tract Diseases
Nicotine
Mental Disorders
HIV Infections
Lung Neoplasms
Lung Diseases
Sexually Transmitted Diseases
Substance-Related Disorders
Retroviridae Infections

Additional relevant MeSH terms:
Thoracic Neoplasms
Communicable Diseases
Sexually Transmitted Diseases, Viral
Slow Virus Diseases
Disorders of Environmental Origin
Infection
Compulsive Behavior
Neoplasms by Site
Respiratory Tract Diseases
Mental Disorders
Lung Neoplasms
Substance-Related Disorders
Retroviridae Infections
Respiratory Tract Neoplasms
RNA Virus Infections
Behavior, Addictive
Immune System Diseases
Acquired Immunodeficiency Syndrome
Impulsive Behavior
Immunologic Deficiency Syndromes
Virus Diseases
Neoplasms
HIV Infections
Lung Diseases
Sexually Transmitted Diseases
Lentivirus Infections

ClinicalTrials.gov processed this record on May 07, 2009